FDA not satisfied with Cadila’s efforts to fix warfarin production, even after 15 responses

Eric Palmer

Cadila Healthcare last week got out in front of bad news by announcing it had received a warning letter from the FDA for two of its Indian plants but was doing all that was asked by the agency. What it didn't explain in the announcement is that it had yet to satisfy the FDA responding 15 times to FDA concerns, or that the FDA was particularly troubled by its manufacturing of the blood thinner .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS